Specifying custom aav production so the batch can be dosed: how aav production and aav vector production scale and method decide the empty capsid fraction long before purification does, why aav purification by affinity alone leaves the separation that matters undone, what aav9 and the other serotypes change about tropism, manufacture and neutralising antibody exposure, how an aav elisa, a cgmp elisa and a his tag elisa each measure something different about the same preparation, what aav analytics and aav testing have to cover before a release decision, and why aav titer quoted without its method is the number most likely to be wrong

Specifying the batch

1. Choose the serotype from the target, then check manufacture. Tropism and immune exposure differ between serotypes, and so does how easily each is produced and purified. A serotype chosen purely on published tropism can be a difficult manufacturing programme, and that is worth knowing before the construct is fixed.
2. Name every titre method in the contract. Genome titre, capsid titre and infectious titre differ by large factors and each depends on its assay design and standard. A batch specification that says a number without a method has specified nothing.
3. Set an empty and partial capsid limit. Capsids carrying no genome or a truncated one contribute to the immune load and not to the effect. Separating them is a real unit operation with a real yield cost, and the limit belongs in the specification rather than in the report.
4. Build the purification around what the dose requires. Affinity capture concentrates the vector; it does not separate full from empty. Density or ion exchange based polishing is what does that, and omitting it is the commonest gap between a research batch and a usable one.
5. Agree the release panel before manufacture. Identity, genome titre, capsid content, purity, residual host protein and DNA, residual plasmid, replication competent vector where applicable, endotoxin and sterility. Agreeing it afterwards means testing retained samples for methods that were not ready.
6. Plan the analytics with the same lead time as the batch. Assays that are not qualified when the batch is released delay everything. Analytical development belongs on the same timeline as process development, not behind it.

Titre is a contract term, not a measurement

Because the number depends so heavily on method, the useful approach is to treat titre as something negotiated and defined rather than reported. Name the assay, the standard, the amplicon position where relevant, and the acceptance range, and require the same method for every batch.

Then have one batch measured independently. A single cross check early tells you whether your partner's number and the rest of the world's number are the same size, and it is far cheaper than discovering a systematic offset during a study.

Plasmid supply is the quiet constraint

Triple transfection processes consume large quantities of graded plasmid, and plasmid lead times at that grade are long. Programmes routinely lose weeks because the vector slot was booked before the plasmid was ordered.

Sequence the ordering: plasmid grade decided, plasmid ordered, then the manufacturing slot. Doing it the other way round produces an idle suite and an invoice.

Common questions

Why do two laboratories report different titres for one batch?

Different assay designs, different standards and sometimes different primer positions within the genome. It is the norm rather than the exception, which is why the method belongs in the specification and an independent cross check is worth running once.

Do empty capsids matter?

Yes. They add to the total capsid load without contributing effect, which affects the immune response and the interpretation of dose. Regulators expect the fraction to be measured and controlled, not merely reported.

Is affinity purification enough?

For research use often yes. For anything dosed, no, because affinity resins bind the capsid regardless of what is inside it. A polishing step that separates by density or charge is required to control the full fraction.

What lead time should be assumed?

Longer than the manufacturing slot suggests, because plasmid supply, analytical qualification and release testing all sit around it. Booking a slot without those in place produces an expensive wait.

Browse by service class

• Compare Gene synthesis on advertised prices